thalidomidePROTAC,SARS-CoV-2

Li-Na Guo1, Yu-Hua Li1, Rou-Yu Zhu2

  • 1NHC Key Lab of Reproduction Regulation, Shanghai Engineering Research Center of Reproductive Health Drug and Devices, Shanghai-MOST Key Laboratory of Health and Disease Genomics, Shanghai Institute for Biomedical and Pharmaceutical Technologies Shanghai 200237 China guoln90@126.com li_yuhua@163.com diaohua@sibpt.cn.

RSC medicinal chemistry
|January 15, 2026
PubMed
概括

新的蛋白质分解向化体 (PROTACs) 有效地降低了SARS-CoV-2主要蛋白酶 (Mpro). 这些PROTAC提供了一个有前途的催化降解策略,用于对抗药物耐药的病毒标.